The European healthcare technology and medical technology sectors have transitioned into a period of disciplined industrial maturity. The speculative, venture-subsidised fragmentation of the early 2020s has given way to a transactional ecosystem where strategic value is defined by clinical utility, regulatory resilience, and technological defensibility. This maturation has driven a corresponding transformation in mergers and acquisitions advisory. This shift has reopened the